

Claim 153: The method of claim 145, comprising contacting said sample with a nucleic acid molecule which specifically hybridizes to a nucleic acid molecule which codes for or expresses said protein.

Claim 154: The method of claim 145, comprising assaying said sample for shed cancer associated antigen.

Claim 155: The method of claim 145, comprising assaying said sample for antibodies specific for said cancer associated antigen, by contacting said sample with said cancer associated antigen.

Claim 156: Method for screening for a cancerous condition comprising assaying a sample taken from a subject for an immunoreactive cell specific for a peptide derived from a cancer associated antigen encoded by SEQ ID NO: 15, 22 or 26 complexed to an MHC molecule, presence of said immunoreactive cell being indicative of said cancerous condition.


Claim 157: An isolated nucleic acid molecule consisting of a nucleotide sequence defined by SEQ ID NO: 15, 22 or 26.

**REMARKS**

Entry of the foregoing amendment is requested.

Respectfully submitted,

FULBRIGHT & JAWORSKI, LLP

By   
Norman D. Hanson  
Reg. No. 30,946

666 Fifth Avenue

New York, New York 10103  
(212) 318-3000

[illegible]